ScaiPod: A New Initiative to Transform Immuno-Oncology

Scailyte announces the launch of ScaiPod, an initiative to address clinical challenges in immuno-oncology. The goal is to accelerate the development of clinical biomarkers to respond to immune checkpoint inhibitors (ICIs) and enable precision immuno-oncology. ScaiPod also intends to provide clarity on ICI resistance mechanisms and immune-related adverse effects. This initiative could lead to the creation of new oncology therapies.

ScaiPod will combine single-cell omics, imaging, and clinical data to facilitate the development of biomarker assays and provide a comprehensive immuno-oncology database. This aims to reduce risks in the development of new medicines and guide the selection of appropriate treatments for patients, potentially saving millions of lives.

Dr. Jakob Kather highlights ScaiPod's powerful, multi-modal approach, combining imaging data and large-scale molecular characterization using artificial intelligence. Additionally, Peter Nestorov, co-founder and CEO of Scailyte, discusses the goal of processing samples from 5,000 patients of various cancer indications, working with academic and industry partners to bring the right treatment to the right patient.

A founding study of ScaiPod, in collaboration with the research group of Prof. Mitch Levesque, will focus on 250 melanoma patients. The aim is to identify predictive biomarkers prior to ICI treatment. This multinational collaboration also aims to establish an automated and standardized omics clinical workflow, promising significant advances in the field of immuno-oncology.